| 내용 |
1, Attrition in drug discovery and development / Scott Boyer, Clive Brealey and Andrew M. Davis. - 2, Compound attrition at the pre-clinical phase / Cornelis E.C.A. Hop. - 3, Attrition in phase I / Dennis A. Smith and Thomas A. Baillie. - 4, Compound attrition in phase II/III / Alexander Alex, C. John Harris, Wilma W. Keighley and Dennis A. Smith. - 5, Post-marketing attrition / Dennis A. Smith. - 6, Influence of the regulatory environment on attrition / Robert T. Clay. - 7, Experimental screening strategies to reduce attrition risk / Marie-Claire Peakman, Matthew Troutman, Rose Gonzales and Anne Schmidt. - 8, Medicinal chemistry strategies to prevent compound attrition / J. Richard Morphy. - 9, Influence of phenotypic and target-based screening strategies on compound attrition and project choice / Andrew Bell, Wolfgang Fecke and Christine Williams. - 10, In silico approaches to address compound attrition / Peter Gedeck, Christian Kramer, Richard Lewis. - 11, Current and future strategies for improving drug discovery efficiency / Peter Mbugua Njogu and Kelly Chibale. - 12, Impact of investment strategies, organizational structure and corporate environment on attrition, and future investment strategies to reduce attrition / Geoff Lawton.
|
